To evaluate the influence of HIV-1 tropism on virologic and immunologic responses in antiretroviral-naïve HIV-1-infected patients enrolled in the ArTEN trial (atazanavir/r vs. nevirapine along with tenofovir/emtricitabine).
Purpose
To evaluate the influence of HIV-1 tropism on virologic and immunologic responses in antiretroviral-naïve HIV-1-infected patients enrolled in the ArTEN trial (atazanavir/r vs. nevirapine along with tenofovir/emtricitabine).
Methods
Baseline plasma samples from patients enrolled in the ArTEN trial were tested genotypically for HIV tropism using geno2pheno (5.75% FPR) and PSSM (enhanced for X4 detection; Poveda et al, JAC 2009 At weeks 24 and 48, the proportion of patients with VL <50 copies/mL was similar in both treatment arms, but lower in those with X4 than R5 viruses. The multivariate analysis confirmed HIV tropism as independent predictor of virologic response at week 24, along with baseline VL and CD4 count. In contrast, the extent of CD4 gains was not significantly determined by HIV tropism, but it was by baseline VL, CD4 count and treatment arm. 
